Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average – Time to Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $25.21 and traded as high as $25.21. Capricor Therapeutics shares last traded at $24.72, with a volume of 1,131,063 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CAPR shares. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. Roth Mkm increased their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. HC Wainwright boosted their target price on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Finally, Maxim Group upped their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Trading Up 7.3%

The company has a market cap of $1.13 billion, a price-to-earnings ratio of -13.73 and a beta of 0.38. The company has a fifty day moving average price of $25.21 and a two-hundred day moving average price of $13.09.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). Sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at $1,555,000. Moody Aldrich Partners LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at $6,025,000. Two Sigma Investments LP raised its stake in Capricor Therapeutics by 128.3% during the third quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock worth $2,565,000 after acquiring an additional 199,959 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its holdings in shares of Capricor Therapeutics by 1,629.9% during the third quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock valued at $1,379,000 after acquiring an additional 180,234 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.